

CORRIGENDA

Daly R. J., Carrick N. and Darbre P. D.: Progression to steroid autonomy is accompanied by altered sensitivity to growth factors in S115 mouse mammary tumor cells. *J. Steroid Biochem. Molec. Biol.* 54 (1995) 21–29.

In the above paper, the key in the figure legends to Figs 3 and 4 does not match the figures. The correct Figs 3 and 4 and their legends are reproduced below.




Fig. 3. Interaction of growth factors with each other and with testosterone on the growth of androgen responsive S115 + A and androgen insensitive S115-A mouse mammary tumour cells in monolayer culture at 2% DCFCS. Cells were grown without steroid or growth factor addition (\square) or with 3.5×10^{-8} testosterone (\blacksquare), 10 ng/ml rbFGF (▨), 10^{-10} M TGF β_1 (▩), 10 ng/ml rbFGF + 10^{-10} M TGF β_1 (▧), 10 ng/ml rbFGF + 10^{-10} M TGF β_1 + 100 ng/ml EGF + 1 μ g/ml insulin (▤), 3.5×10^{-8} testosterone + 10 ng/ml rbFGF (▥), 3.5×10^{-8} testosterone + 10^{-10} M TGF β_1 (▦). Cell growth was expressed as the mean number of cell doublings in 6 days and error bars show the standard error from triplicate estimates.




Fig. 4. Effect of growth factors on the growth of androgen responsive S115 + A and androgen insensitive S115-A mouse mammary tumour cells in suspension culture at 2% DCFCS. Cells were grown without steroid or growth factor addition (\square) or with 3.5×10^{-8} testosterone (\blacksquare), 10 ng/ml rbFGF (▨), 10^{-10} TGF β_1 (▩), 10 ng/ml rbFGF + 10^{-10} M TGF β_1 (▧), 10 ng/ml rbFGF + 10^{-10} M TGF β_1 + 100 ng/ml EGF + 1 μ g/ml insulin (▤), 3.5×10^{-8} testosterone + 10 ng/ml rbFGF (▥), 3.5×10^{-8} testosterone + 10^{-10} M TGF β_1 (▦). Cell growth was expressed as the mean number of cell doublings in 7 days and error bars show the standard error from triplicate estimates.

Wajchenberg B. L., Mendonca B. B., Liberman B., Pereira M. A. A. and Kirschner M. A.: Ectopic ACTH syndrome. *J. Steroid Biochem. Molec. Biol.* 53 (1995) 139–151.

In the last paragraph on p. 143 of the above paper, there is an inaccuracy in the quote from the paper by Stewart *et al.*, *Clin. Endocr. (Oxf.)* 40 (1994) 199–204. The last sentence of the quote (on p. 144) reads “However, there is the possibility that a patient with a non-pituitary tumor may over-process POMC resulting in only authentic ACTH in the circulation”. While Stewart *et al.* agree that this is a possibility they believe the opposite, and request that the sentence be modified to “Thus, patients with non-pituitary tumors may under-process POMC resulting in relatively little authentic ACTH in the circulation”.